This June is shaping up to be a historic Alzheimer’s and Brain Awareness Month with approval yesterday of BIO member Biogen’s new Alzheimer’s drug—which could change treatment for this insidious disease.
Biogen’s Aduhelm is the first treatment to address a likely cause of Alzheimer’s—and the first new treatment for the disease in nearly two decades.
“Currently available therapies only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer’s,”said Patrizia Cavazzoni, M.D., Director of the FDA’s Center for Drug Evaluation and Research. “As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research and innovation.”
The drug eliminates “clumps of a toxic protein believed to destroy neurons and cause dementia,”explains STAT News.
What they’re saying: “The approval of Aduhelm represents a crucial inflection point in our collective battle against Alzheimer’s disease. By addressing a defining pathology of the disease, this novel therapy has the potential to help fundamentally change the way patients are diagnosed and treated,” said Biogen CEO Michel Vounatsos—read his entire letter.
The next steps: “Instead of judging Biogen’s treatment solely on its effects on cognition, the FDA granted a conditional approval based on Aduhelm’s ability to clear the toxic proteins,” continues STAT. “In order to continue marketing the drug, Biogen will need to complete a large clinical trial to confirm that removing the plaque has cognitive benefits.”
Join us: Biogen CEO Michel Vounatsos will speak at BIO Digital on June 17 during a one-on-one conversation about the company’s commitment to corporate responsibility and the future of biotechnology.
More Health Care News:
Modern Healthcare: With the help of Black women, we can boost vaccine acceptance and uptake
“Black mothers, Black grandmothers, Black aunts, Black teachers—figures of unique moral authority in the community—need to be enlisted,” write BIO’s Dr. Michelle McMurry-Heath and Linda Goler Blount, President and CEO of Black Women’s Health Imperative.
NPR: The CDC's No. 2 official says the U.S. isn't ready for another pandemic
“The United States was unprepared for the coronavirus, the response ‘wasn't a good performance,’ and there's still ‘a lot of work to do’ to get ready for the next pandemic when it comes,” said Dr. Anne Schuchat, retiring principal deputy director of the CDC.